Banner Life Sciences mourns the loss of its president, Michael Lytton...

Specialty Pharmaceuticals

Novel Formulations Solving Unmet Clinical Needs

OUR LEADERSHIP 

Franck Rousseau, M.D.

Chief Operating Officer

Franck Rousseau became COO of Banner Life Sciences in 2016. Before joining Banner Life Sciences, Dr. Rousseau had been Chief Medical Officer of two North Carolina-based companies, Tranzyme and Ocera.

After training as a physician, Franck rose through the clinical development ranks at GlaxoWellcome and then joined a startup biotech, Triangle Pharmaceuticals, in 1997 where he served as Chief Medical Officer until the company’s acquisition by Gilead in 2003. Franck then ran Gilead’s site in Durham, NC from 2003-2010.

Dr. Rousseau holds a B.A. from the University of Paris 6, and his M.D. from the University of Paris, College of Medicine. Dr. Rousseau has a Degree of Epidemiology and Nosocomial Infections from the University of Paris 7, and in Biostatistics from University Paris 2, Paris, France.

Bart J. Dunn

Vice President, Business Development & Licensing 

Bart Dunn joined Banner Life Sciences in 2013 as Vice President of Business Development & Licensing. Prior to that, Mr. Dunn served as Vice President of Corporate Development & Licensing and was a corporate officer at NuPathe, Inc., a publicly traded biotech start-up focused on disorders of the central nervous system. 

Between 2006 and 2011, Mr. Dunn served on the senior leadership team as Vice President of Business Development & Strategic Planning at Inspire Pharmaceuticals. There, he oversaw all corporate development and licensing activities, helping lead the company through a strategic acquisition by global pharmaceutical leader Merck & Co. 

Mr. Dunn joined Inspire after leaving Pfizer Inc., where he was Director of Business Development in the Corporate Development and Strategic Planning group. During his 16-year tenure at Pfizer, he served in a variety of management capacities: strategic planning, finance, and operations. 

Mr. Dunn also spent seven years at PepsiCo, holding positions in business planning, corporate tax, and internal audit. 

An accomplished financial and corporate development executive, Mr. Dunn has more than 25 years of experience spanning large-cap, mid-cap specialty, and start-up companies in the pharmaceutical and over-the-counter drug industries. He has led or participated in more than 30 M&A, licensing and divestiture transactions valued at more than $4 billion. He holds an MBA from Saint Joseph's University, a BBA from Pace University, and he is a Certified Public Accountant.

Tom Lategan

Vice President of Regulatory Affairs

Tom Lategan joined Banner Life Sciences in 2015 as Vice President of Regulatory Affairs. Prior to that, Dr. Lategan served as Vice President of Regulatory Affairs and Head of Clinical Operations at NeurAxon, Inc., a pharmaceutical start-up focused on nitric oxide synthase inhibition.

Between 2000 and 2007, Dr. Lategan served on the senior leadership team as Vice President of Regulatory Affairs at Actelion. There, he oversaw all US regulatory activities, helping lead the company through approval and launch of Tracleer® (bosentan) and Zavesca® (miglustat).

Dr. Lategan joined Actelion after leaving The Medicines Company,  Inc., where he was Vice President of Product Value. During his tenure at The Medicines Company, he oversaw the submission of the Angiomax® (bivalirudin) NDA and conduct of preclinical and clinical studies.

Dr. Lategan also spent nine years at Hoffmann-La Roche, both in Switzerland and the US, holding positions of increasing responsibilities in regulatory and medical affairs.

Dr. Lategan has more than 20 years of experience spanning large-cap, and start-up companies in the pharmaceutical industry. He holds an B.Sc. in pharmacology from Aberdeen University in Scotland, and a D.Phil. from Oxford University.

James W. Coulston

Executive Director, Finance

James Coulston joined Banner Life Sciences in August of 2015 as Executive Director, Finance. Prior to joining Banner Life Science, Mr. Coulston was Senior Director, Finance and Controller at Targacept, Inc., a publicly traded biopharmaceutical company, where he held positions of increasing responsibility from 2007 to 2015. From 1999 to 2006, Mr. Coulston held positions of increasing responsibility in assurance and advisory services at Ernst & Young.

Mr. Coulston holds an undergraduate degree in accounting and a Master of Accounting degree from North Carolina State University and is a Certified Public Accountant in the state of North Carolina.

Jason Vaughn, Ph.D.

Vice President Pharmaceutical Development

Dr. Jason M. Vaughn has 12 years of pharmaceutical development experience.  He spent several years at PharmaForm LLC in various positions including Associate Director of Analytical and Formulation Development, Director of Operations and eventually Vice President of Operations. In these positions, he focused on the development of novel abuse deterrent formulations for internal and external clients.   He then joined DPT Laboratories as Director of Formulation Development where he led a team that developed formulations for liquids and semisolids. Following this, he joined Enavail LLC as Director of Research.  In 2012, Jason joined Patheon as Director of Scientific Affairs in the Cincinnati facility leading the development of formulations focused on modified release oral dosage forms. Jason now serves as Vice President of Pharmaceutical Development for Banner Life Sciences where he focuses on novel formulations for the treatment of clinical unmet needs. He received a B.S. in Pharmacy and a Ph.D. in Pharmaceutics from the University of Texas at Austin.

Connie Cosentino

Vice President Clinical Operations

With more than 19 years of experience in the Biotech/Pharmaceutical industry and 10+ years of hands-on managerial experience overseeing clinical operation teams, Connie joined Banner Life Sciences in July 2016 as Vice President Clinical Operations. Prior to joining Banner Life Sciences, she served as Senior Director of Clinical Operations at Ocera Therapeutics. At Ocera, Connie initiated and conducted the key Phase II study in patients with acute Hepatic Encephalopathy (HE), an orphan disease, and the follow-on oral program for prevention of HE. Prior to Ocera, Connie led the Clinical Operations at Tranzyme Pharma in RTP, Durham, where she was responsible to deliver global phase 3 pivotal trials and phase 2 studies in the GI space. Prior to her employment at Tranzyme, she was responsible for all clinical operations at the Durham site of Gilead Sciences where she was responsible for delivering and conducting clinical trials under IND’s leading to multiple NDAs of products currently selling multi-billion dollars per year. Ms. Cosentino is a Registered Nurse with an Associate of Science in Accounting degree.